Federal Circuit upholds Myriad patents in ‘meatier’ ruling; holds the 'Mayo'
This article was originally published in Scrip
Executive Summary
In what largely was expected to be a repeat of its July 2011 ruling, which went mostly in favor on the first go-around for Myriad Genetics on its claims for patenting the BRCA genes, the US Court of Appeals for the Federal Circuit on 16 August arrived at the same conclusion – even using much of the same language as before in an almost cut-and-paste fashion in its latest opinion.